Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -24.44% is 54% above its 5-year average of -52.81%, near the high end of its 5-year range (-77.20%–-24.44%).
48.20% above its 12-month average of -47.18%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -12.71%.
RETURN ON ASSETS (ROA)
-24.44%
RETURN ON ASSETS (ROA) AVG TTM
-47.18%
RETURN ON ASSETS (ROA) AVG 3Y
-56.01%
RETURN ON ASSETS (ROA) AVG 5Y
-52.81%
RETURN ON ASSETS (ROA) AVG 10Y
-35.29%
RETURN ON ASSETS (ROA) AVG 15Y
-34.70%
RETURN ON ASSETS (ROA) AVG 20Y
-29.77%
CURRENT VS TTM AVG
+48.20%
CURRENT VS 3Y AVG
+56.36%
CURRENT VS 5Y AVG
+53.72%
CURRENT VS 10Y AVG
+30.74%
CURRENT VS 15Y AVG
+29.56%
CURRENT VS 20Y AVG
+17.91%
SECTOR MEDIAN · HEALTHCARE
-30.75%
median of 749 covered companies
CURRENT VS SECTOR MEDIAN
+20.52%
vs the sector median at left
Lexicon Pharmaceuticals, Inc.
Market Cap
$777.34M
Return on Assets (ROA)
-24.44%
TTM Avg
-47.18%
3Y Avg
-56.01%
5Y Avg
-52.81%
Market Cap
$777.14M
Return on Assets (ROA)
-36.55%
TTM Avg
-44.22%
3Y Avg
-44.22%
5Y Avg
-44.22%
Market Cap
$769.49M
Return on Assets (ROA)
1.14%
TTM Avg
0.56%
3Y Avg
-13.91%
5Y Avg
-9.14%
Market Cap
$783.39M
Return on Assets (ROA)
-49.09%
TTM Avg
-55.91%
3Y Avg
-48.67%
5Y Avg
-44.21%
Market Cap
$792.28M
Return on Assets (ROA)
-13.47%
TTM Avg
-22.22%
3Y Avg
-41.40%
5Y Avg
-40.82%
Market Cap
$760.10M
Return on Assets (ROA)
-32.91%
TTM Avg
-25.26%
3Y Avg
-23.04%
5Y Avg
-20.66%
Market Cap
$793.24M
Return on Assets (ROA)
-8.70%
TTM Avg
6.33%
3Y Avg
-16.09%
5Y Avg
-46.82%
Market Cap
$796.60M
Return on Assets (ROA)
-5.26%
TTM Avg
0.19%
3Y Avg
-3.34%
5Y Avg
-3.22%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexicon Pharmaceuticals, Inc. (LXRX) | $777.34M | -24.44% | -47.18% | -56.01% | -52.81% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $777.14M | -36.55% | -44.22% | -44.22% | -44.22% |
| Mesa Laboratories, Inc. (MLAB)vs › | $769.49M | 1.14% | 0.56% | -13.91% | -9.14% |
| Sana Biotechnology, Inc. (SANA)vs › | $783.39M | -49.09% | -55.91% | -48.67% | -44.21% |
| Geron Corporation (GERN)vs › | $792.28M | -13.47% | -22.22% | -41.40% | -40.82% |
| Design Therapeutics, Inc. (DSGN)vs › | $760.10M | -32.91% | -25.26% | -23.04% | -20.66% |
| Apnimed, Inc. (APMD)vs › | $790.49M | N/A | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $793.24M | -8.70% | 6.33% | -16.09% | -46.82% |
| AdaptHealth Corp. (AHCO)vs › | $796.60M | -5.26% | 0.19% | -3.34% | -3.22% |
| InMode Ltd. (INMD)vs › | $806.17M | 10.76% | 17.66% | 20.82% | 23.86% |
ROA
-24.4%
ROE
-35.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -27.21% |
| 2024-12-31 | -67.15% |
| 2023-12-31 | -77.20% |
| 2022-12-31 | -52.47% |
| 2021-12-31 | -64.10% |
| 2020-12-31 | -28.74% |
| 2019-12-31 | 31.15% |
| 2018-12-31 | -42.43% |
| 2017-12-31 | -29.56% |
| 2016-12-31 | -29.74% |
| 2015-12-31 | -0.71% |
| 2014-12-31 | -21.28% |
| 2013-12-31 | -37.98% |
| 2012-12-31 | -29.64% |
| 2011-12-31 | -26.99% |
| 2010-12-31 | -27.74% |
| 2009-12-31 | -32.12% |
| 2008-12-31 | -29.39% |
| 2007-12-31 | -15.92% |
| 2006-12-31 | -28.54% |
| 2005-12-31 | -16.60% |
| 2004-12-31 | -22.25% |
| 2003-12-31 | -22.59% |
| 2002-12-31 | -29.57% |
| 2001-12-31 | -14.66% |
| 2000-12-31 | -11.78% |
| 1999-12-31 | -56.05% |
